Evaluation of the Novel 4R Oncology Care Planning Model in Breast Cancer: Impact on Patient Self-Management and Care Delivery in Safety-Net and Non-Safety-Net Centers.


Journal

JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685

Informations de publication

Date de publication:
08 2021
Historique:
entrez: 10 8 2021
pubmed: 11 8 2021
medline: 3 11 2021
Statut: ppublish

Résumé

Optimal cancer care requires patient self-management and coordinated timing and sequence of interdependent care. These are challenging, especially in safety-net settings treating underserved populations. We evaluated the 4R Oncology model (4R) of patient-facing care planning for impact on self-management and delivery of interdependent care at safety-net and non-safety-net institutions. Ten institutions (five safety-net and five non-safety-net) evaluated the 4R intervention from 2017 to 2020 with patients with stage 0-III breast cancer. Data on self-management and care delivery were collected via surveys and compared between the intervention cohort and the historical cohort (diagnosed before 4R launch). 4R usefulness was assessed within the intervention cohort. Survey response rate was 63% (422/670) in intervention and 47% (466/992) in historical cohort. 4R usefulness was reported by 79.9% of patients receiving 4R and was higher for patients in safety-net than in non-safety-net centers (87.6%, 74.2%, 4R Oncology was useful to patients and significantly improved self-management and delivery of interdependent care, but gaps remain. Model enhancements and further evaluations are needed for broad adoption. Patients in safety-net settings benefited from 4R at similar or higher rates than non-safety-net patients, indicating that 4R may reduce care disparities.

Identifiants

pubmed: 34375560
doi: 10.1200/OP.21.00161
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1202-e1214

Auteurs

Julia R Trosman (JR)

Center for Business Models in Healthcare, Glencoe, IL.
Northwestern University Feinberg School of Medicine, Chicago, IL.

Christine B Weldon (CB)

Center for Business Models in Healthcare, Glencoe, IL.
Northwestern University Feinberg School of Medicine, Chicago, IL.

Bruce D Rapkin (BD)

Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY.
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York, NY.

Al B Benson (AB)

Northwestern Medicine, Chicago, IL.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

Della F Makower (DF)

Montefiore Medical Center, Bronx, NY.

Su-Ying Liang (SY)

Sutter Health-Palo Alto Medical Foundation Research Institute, Palo Alto, CA.

Swati A Kulkarni (SA)

Northwestern Medicine, Chicago, IL.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

Claudia B Perez (CB)

Rush University Health System, Chicago, IL.

Shelly S Lo (SS)

Loyola University Medical Center, Maywood, IL.

Editha A Krueger (EA)

Radiology Associates of Appleton, Appleton, WI.

Alyssa D Throckmorton (AD)

Baptist Cancer Center, Memphis, TN.

Christopher Gallagher (C)

Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC.

Kent Hoskins (K)

Division of Medical Oncology, University of Illinois at Chicago College of Medicine, Chicago, IL.

Cathleen M Schaeffer (CM)

Division of Medical Oncology, University of Illinois at Chicago College of Medicine, Chicago, IL.

Jennifer Van Horn (J)

Banner MD Anderson Cancer Center, Loveland, CO, Formerly Cheyenne Regional Medical Center, Cheyenne, WY.

Lidia Schapira (L)

Stanford University and Stanford Cancer Institute, Stanford, CA.

Arliene Ravelo (A)

Genentech Inc, South San Francisco, CA.

Elaine Yu (E)

Genentech Inc, South San Francisco, CA.

William J Gradishar (WJ)

Northwestern Medicine, Chicago, IL.
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH